A Study to Evaluate the Effect of VX-548 on the QT/QTc Interval in Healthy Participants
Status:
Not yet recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the effects of clinical and high clinical exposures
of VX-548 and its metabolite on QTcF, and the safety, tolerability, pharmacokinetics (PK),
and pharmacodynamics (PD) of VX-548 and its metabolite.
Phase:
Phase 1
Details
Lead Sponsor:
Vertex Pharmaceuticals Incorporated
Treatments:
Moxifloxacin Norgestimate, ethinyl estradiol drug combination